BR112014028801A2 - ensaios com base em célula interrogatória para identificar marcadores de toxicidade induzida por fármaco - Google Patents

ensaios com base em célula interrogatória para identificar marcadores de toxicidade induzida por fármaco

Info

Publication number
BR112014028801A2
BR112014028801A2 BR112014028801A BR112014028801A BR112014028801A2 BR 112014028801 A2 BR112014028801 A2 BR 112014028801A2 BR 112014028801 A BR112014028801 A BR 112014028801A BR 112014028801 A BR112014028801 A BR 112014028801A BR 112014028801 A2 BR112014028801 A2 BR 112014028801A2
Authority
BR
Brazil
Prior art keywords
induced toxicity
interrogative
cell
based assays
drug
Prior art date
Application number
BR112014028801A
Other languages
English (en)
Inventor
Rajin Narain Niven
Sarangarajan Rangaprasad
K Vishnudas Vivek
Original Assignee
Berg Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berg Llc filed Critical Berg Llc
Publication of BR112014028801A2 publication Critical patent/BR112014028801A2/pt

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/50—Mutagenesis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pathology (AREA)
  • Cardiology (AREA)
  • Physiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)

Abstract

abstract described herein is a discovery platform technology for analyzing a drug-induced toxicity condition, such as cardiotoxicity via model building. *********************************** tradução do resumo resumo patente de invenção: "ensaios com base em célula interrogatória para identificar marcadores de toxicidade induzida por fármaco". é descrita aqui uma descoberta de tecnologia de plataforma para analisar uma condição de toxicidade induzida por fármaco, tal como cardiotoxicidade por meio de modelo de construção. 23104025v1 1/1 23104025v1
BR112014028801A 2012-05-22 2012-09-07 ensaios com base em célula interrogatória para identificar marcadores de toxicidade induzida por fármaco BR112014028801A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261650462P 2012-05-22 2012-05-22
PCT/US2012/054323 WO2013176694A1 (en) 2012-05-22 2012-09-07 Interrogatory cell-based assays for indentifying drug-induced toxicity markers

Publications (1)

Publication Number Publication Date
BR112014028801A2 true BR112014028801A2 (pt) 2017-07-25

Family

ID=49621779

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014028801A BR112014028801A2 (pt) 2012-05-22 2012-09-07 ensaios com base em célula interrogatória para identificar marcadores de toxicidade induzida por fármaco

Country Status (14)

Country Link
US (3) US20130315885A1 (pt)
EP (1) EP2852839A4 (pt)
JP (3) JP6219934B2 (pt)
KR (1) KR20150014986A (pt)
CN (2) CN107449921A (pt)
AU (1) AU2012381038B2 (pt)
BR (1) BR112014028801A2 (pt)
CA (1) CA2874432A1 (pt)
EA (1) EA201492178A1 (pt)
HK (1) HK1208905A1 (pt)
IL (1) IL235717B (pt)
MX (1) MX2014013875A (pt)
SG (2) SG10201609654PA (pt)
WO (1) WO2013176694A1 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150023949A1 (en) * 2012-03-05 2015-01-22 Berg Llc Compositions and methods for diagnosis and treatment of pervasive developmental disorder
MX2014013875A (es) 2012-05-22 2015-06-04 Berg Llc Ensayo basado en celulas interrogadoras para identificar marcadores de toxicidad inducida por medicamentos.
EP2895861A4 (en) 2012-09-12 2016-06-22 Berg Llc USE OF MARKERS FOR THE IDENTIFICATION OF CARDIOTOXIC AGENTS
US9449284B2 (en) * 2012-10-04 2016-09-20 Nec Corporation Methods and systems for dependency network analysis using a multitask learning graphical lasso objective function
CA2933446A1 (en) * 2013-12-13 2015-06-18 The Governors Of The University Of Alberta Systems and methods of selecting compounds with reduced risk of cardiotoxicity
CN103923212A (zh) * 2014-03-31 2014-07-16 天津市应世博科技发展有限公司 Ehd2抗体及其在制备乳腺癌免疫组化检测试剂中的应用
WO2015183173A1 (en) * 2014-05-28 2015-12-03 Grafström Roland In vitro toxicogenomics for toxicity prediction
KR102662004B1 (ko) 2014-09-11 2024-04-29 버그 엘엘씨 환자 데이터에 기반한 헬스케어 진단 및 치료를 위한 베이지안 인과 관계 네트워크 모델
KR101856599B1 (ko) * 2015-02-06 2018-05-11 한국과학기술원 분비 대사체 분석을 통한 간독성 약물 스크리닝 방법
EP3271451A4 (en) * 2015-03-20 2018-09-19 Hurel Corporation Methods for characterizing time-based hepatotoxicity
CN104965998B (zh) * 2015-05-29 2017-09-15 华中农业大学 多靶标药物和/或药物组合的筛选方法
US10068027B2 (en) 2015-07-22 2018-09-04 Google Llc Systems and methods for selecting content based on linked devices
MX2018005352A (es) * 2015-10-30 2018-08-14 Ultragenyx Pharmaceutical Inc Metodos y composiciones para el tratamiento de amiloidosis.
WO2018053006A1 (en) * 2016-09-13 2018-03-22 Dana-Farber Cancer Institute, Inc. Methods and compositions for the positive selection of protein destabilizers
JP6940920B2 (ja) * 2017-02-04 2021-09-29 アナバイオス コーポレーション 医薬誘発性の変力作用および不整脈誘発のリスクを予測するためのシステムおよび方法
JP7032723B2 (ja) * 2017-07-21 2022-03-09 公立大学法人福島県立医科大学 薬剤の心毒性評価方法及びそのための試薬又はキット
CN108388768A (zh) * 2018-02-08 2018-08-10 南京恺尔生物科技有限公司 利用生物知识搭建的神经网络模型的生物特性预测方法
CN109182260A (zh) * 2018-09-11 2019-01-11 邵勇 一种体外培养胎膜间充质干细胞的方法
EP3915121A1 (en) 2019-01-23 2021-12-01 The Regents Of The University Of Michigan Methods and system for the reconstruction of drug response and disease networks and uses thereof
JP2022523564A (ja) 2019-03-04 2022-04-25 アイオーカレンツ， インコーポレイテッド 機械学習を使用するデータ圧縮および通信
JP7404648B2 (ja) 2019-04-25 2023-12-26 富士通株式会社 治療薬提示方法、治療薬提示装置、及び治療薬提示プログラム
KR20230061566A (ko) * 2020-09-24 2023-05-08 큐리스 테크놀로지스 리미티드 Ai-칩-온-칩, 임상 예측 엔진
WO2022087540A1 (en) * 2020-10-23 2022-04-28 The Regents Of The University Of California Visible neural network framework
CN114591980A (zh) * 2020-12-04 2022-06-07 深圳华大生命科学研究院 Cars基因突变体及其应用
CN113035298B (zh) * 2021-04-02 2023-06-20 南京信息工程大学 递归生成大阶数行限制覆盖阵列的药物临床试验设计方法
CN114420200A (zh) * 2022-01-19 2022-04-29 时代生物科技（深圳）有限公司 一种功能性肽的筛选方法
CN116286900B (zh) * 2022-10-28 2024-04-26 昆明理工大学 一种乙酸渗透酶A基因RkAcpa及其应用
CN115424741B (zh) * 2022-11-02 2023-03-24 之江实验室 基于因果发现的药物不良反应信号发现方法及系统
CN115878818B (zh) * 2023-02-21 2023-05-30 创意信息技术股份有限公司 一种地理知识图谱构建方法、装置、终端及存储介质

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6951924B2 (en) * 1997-03-14 2005-10-04 Human Genome Sciences, Inc. Antibodies against secreted protein HTEBYII
WO2002051439A2 (en) 2000-12-22 2002-07-04 Medlyte, Inc. Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
US7447594B2 (en) * 2001-07-10 2008-11-04 Ocimum Biosolutions, Inc. Molecular cardiotoxicology modeling
US20070054269A1 (en) * 2001-07-10 2007-03-08 Mendrick Donna L Molecular cardiotoxicology modeling
JP2005517400A (ja) * 2001-07-10 2005-06-16 ジーン ロジック インコーポレイテッド 心臓毒分子毒性モデリング
JP5236856B2 (ja) 2001-11-09 2013-07-17 ライフ テクノロジーズ コーポレーション 遺伝子発現プロファイルを用いる病気の同定、観測及び治療及び生物学的状態の同定
WO2003099320A1 (en) * 2002-05-24 2003-12-04 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
US8263325B2 (en) 2002-11-15 2012-09-11 Ottawa Heart Institute Research Corporation Predicting, detecting and monitoring treatment of cardiomyopathies and myocarditis
US20090169585A1 (en) 2003-10-23 2009-07-02 Resveratrol Partners, Llc Resveratrol-Containing Compositions And Their Use In Modulating Gene Product Concentration Or Activity
ATE546734T1 (de) 2003-12-05 2012-03-15 Cleveland Clinic Foundation Risikomarker für eine herzkreislaufkrankheit
US7883858B2 (en) 2005-01-27 2011-02-08 Institute For Systems Biology Methods for identifying and monitoring drug side effects
US9002652B1 (en) 2005-01-27 2015-04-07 Institute For Systems Biology Methods for identifying and using organ-specific proteins in blood
US20090202995A1 (en) 2005-08-26 2009-08-13 Mendrick Donna L Molecular cardiotoxicology modeling
ATE535612T1 (de) * 2006-03-06 2011-12-15 Ceetox Inc Toxizitätsscreeningverfahren
US8571803B2 (en) * 2006-11-15 2013-10-29 Gene Network Sciences, Inc. Systems and methods for modeling and analyzing networks
AU2008300897B2 (en) * 2007-07-18 2014-12-04 Cellartis Ab Cardiomyocyte-like cell clusters derived from hBS cells
EP2019318A1 (en) * 2007-07-27 2009-01-28 Erasmus University Medical Center Rotterdam Protein markers for cardiovascular events
EP2344181A1 (en) * 2008-09-18 2011-07-20 Universitetet I Oslo Use of ctgf as a cardioprotectant
WO2010144358A1 (en) * 2009-06-08 2010-12-16 Singulex, Inc. Highly sensitive biomarker panels
US20110287437A1 (en) * 2010-05-20 2011-11-24 Hans Marcus Ludwig Bitter Assays to predict cardiotoxicity
US20120058088A1 (en) 2010-06-28 2012-03-08 Resveratrol Partners, Llc Resveratrol-Containing Compositions And Methods Of Use
WO2012024296A1 (en) 2010-08-20 2012-02-23 University Of Miami Arterial repair with cultured bone marrow cells and whole bone marrow
EA201391245A1 (ru) 2011-03-02 2014-05-30 Берг Ллк Интеррогативные клеточные анализы и их применение
MX2014013875A (es) 2012-05-22 2015-06-04 Berg Llc Ensayo basado en celulas interrogadoras para identificar marcadores de toxicidad inducida por medicamentos.
EP2895861A4 (en) 2012-09-12 2016-06-22 Berg Llc USE OF MARKERS FOR THE IDENTIFICATION OF CARDIOTOXIC AGENTS

Also Published As

Publication number Publication date
HK1208905A1 (en) 2016-03-18
EA201492178A1 (ru) 2015-12-30
AU2012381038A1 (en) 2014-11-27
NZ722231A (en) 2018-02-23
IL235717B (en) 2018-08-30
EP2852839A4 (en) 2016-05-11
SG11201407569PA (en) 2014-12-30
JP2018049017A (ja) 2018-03-29
US20190304566A1 (en) 2019-10-03
CN104487842B (zh) 2017-09-08
SG10201609654PA (en) 2017-01-27
CA2874432A1 (en) 2013-11-28
NZ701908A (en) 2016-08-26
CN104487842A (zh) 2015-04-01
AU2012381038B2 (en) 2019-03-07
US20130315885A1 (en) 2013-11-28
IL235717A0 (en) 2015-01-29
US20240161863A1 (en) 2024-05-16
WO2013176694A8 (en) 2014-10-09
CN107449921A (zh) 2017-12-08
JP2020072653A (ja) 2020-05-14
WO2013176694A1 (en) 2013-11-28
US11694765B2 (en) 2023-07-04
MX2014013875A (es) 2015-06-04
KR20150014986A (ko) 2015-02-09
JP2015520375A (ja) 2015-07-16
JP6219934B2 (ja) 2017-10-25
EP2852839A1 (en) 2015-04-01

Similar Documents

Publication Publication Date Title
BR112014028801A2 (pt) ensaios com base em célula interrogatória para identificar marcadores de toxicidade induzida por fármaco
MX357392B (es) Ensayos basados en interrogatorios celulares y uso de los mismos.
BR112012033350A2 (pt) "composição e métodos para modular a via de sinalização de wnt"
DOP2014000093A (es) Compuestos con actividad nematicida
UY34697A (es) Métodos para preparar análogos de nucleótidos
UY34765A (es) Compuestos novedosos.
UY34177A (es) Nuevos compuestos inhibidores de la fosfodiesterasa tipo 10a
CR20120334A (es) Derivados de imidazopiridina como inhibidores de jak
UY34832A (es) TIAZOLES SUSTITUIDOS POR CARBOXAMIDA O SULFONAMIDA Y DERIVADOS RELACIONADOS COMO MODULADORES PARA EL RECEPTOR NUCLEAR HUÉRFANO RORy (lambda)
CO6801678A2 (es) Recubrimiento para abertura arquitectónica que incluye estructuras de células que empujan para abrir
DOP2014000090A (es) Compuestos con actividad nematicida
UY34216A (es) Nuevos compuestos que inhiben la actividad de la Lp-PLA2
BR112012030473A2 (pt) pesticidas baseados em derivados pirrolidina espiroheterocíclicos
BR112015009042A2 (pt) populações de célula renal e usos das mesmas
FR2964744B1 (fr) Test pronostic de l'evolution d'une tumeur solide par analyse d'images
BR112014031959A2 (pt) recipiente de plástico e tampa
BR112013004932A2 (pt) aspectos de identificação sobre uma superfície de um objeto usando análise de pequenas ondulações
CO6640201A2 (es) Moduladores de crth2
CR20160039A (es) Imidazotiazol sulfonamidas como nematicidas
FR2968460B1 (fr) Flasque stockeur d'energie
BR112013028368A2 (pt) novos compostos de hexahidrociclopentapirrolona, hexahidropirrolopirrolona, octahidropirrolopiridinona e octahidropiridinona
BR112015004430A2 (pt) célula de fluxo de permeabilidade e sistema de condutância hidráulica
FR2989719B1 (fr) Partie basse d'une baie coulissante a performances ameliorees.
BR112013028945A2 (pt) novos compostos de hexahidropirroloimidazolona
GB201021475D0 (en) New flame technique for the analysis of samples by their molecular absorptions

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2530 DE 02-07-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]